In our in vivo experiments, it can be found that blocking IL-17A alone can inhibit tumor growth to some extent, but when combined with anti-PD-L1 drugs, cancer tissue expression of PD-L1 is reduced, which makes anti-PD-L1 drugs lose their targets and the anti-tumor effect is diminished. This evidence concerns the gene IL17A and neoplasm.